Intermediate-term survival of robot-assisted versus open radical cystectomy for muscle-invasive and high-risk non-muscle invasive bladder cancer in The Netherlands

Florentien J. Hinsenveld; Joost L. Boormans; Henk G. van der Poel; Deric K. E. van der Schoot; André N. Vis; Katja K. H. Aben; T. J. Arends; P. J. Ausems; D. Baselmans; C. P. A. M. Berger; A. Berrens; H. Bickerstaffe; S. D. Bos; M. Braam; K. T. Buddingh; S. Claus; K. Dekker; T. van Doeveren; S. M. H. Einerhand; L. M. C. L. Fossion; E. J. van Gennep; N. van Ginkel; L. A. Grondhuis Palacios; T. J. N. Hermans; M. M. Hobijn; S. H. van Huystee; M. Jaspers-Valentijn; O. S. Klaver; E. L. Koldewijn; On behalf of the Dutch Cystectomy Snapshot Group; L. Korsten; A. Lenting; K. J. Lentjes; H. B. Luiting; S. van der Meer; J. A. Nieuwenhuijzen; M. A. Noordzij; R. I. Nooter; C. A. W. Notenboom; R. J. A. Oomen; J. G. H. van Roermund; J. de Rooij; H. Roshani; B. P. Schrier; M. A. van der Slot; D. M. Somford; P. J. Stelwagen; A. M. A. Stroux; A. van der West; B. P. Wijsman; W. A. K. M. Windt; P. van Zanten; Sytse C. van Beek

doi:10.1016/j.urolonc.2021.06.018

Intermediate-term survival of robot-assisted versus open radical cystectomy for muscle-invasive and high-risk non-muscle invasive bladder cancer in The Netherlands

Florentien J. Hinsenveld, Joost L. Boormans^*, Henk G. van der Poel, Deric K. E. van der Schoot, André N. Vis, Katja K. H. Aben, T. J. Arends, P. J. Ausems, D. Baselmans, C. P. A. M. Berger, A. Berrens, H. Bickerstaffe, S. D. Bos, M. Braam, K. T. Buddingh, S. Claus, K. Dekker, T. van Doeveren, S. M. H. Einerhand, L. M. C. L. FossionE. J. van Gennep, N. van Ginkel, L. A. Grondhuis Palacios, T. J. N. Hermans, M. M. Hobijn, S. H. van Huystee, M. Jaspers-Valentijn, O. S. Klaver, E. L. Koldewijn, On behalf of the Dutch Cystectomy Snapshot Group, L. Korsten, A. Lenting, K. J. Lentjes, H. B. Luiting, S. van der Meer, J. A. Nieuwenhuijzen, M. A. Noordzij, R. I. Nooter, C. A. W. Notenboom, R. J. A. Oomen, J. G. H. van Roermund, J. de Rooij, H. Roshani, B. P. Schrier, M. A. van der Slot, D. M. Somford, P. J. Stelwagen, A. M. A. Stroux, A. van der West, B. P. Wijsman, W. A. K. M. Windt, P. van Zanten, Sytse C. van Beek

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background: Radical cystectomy with pelvic lymph node dissection is the recommended treatment in non-metastatic muscle-invasive bladder cancer (MIBC). In randomised trials, robot-assisted radical cystectomy (RARC) showed non-inferior short-term oncological outcomes compared with open radical cystectomy (ORC). Data on intermediate and long-term oncological outcomes of RARC are limited. Objective: To assess the intermediate-term overall survival (OS) and recurrence-free survival (RFS) of patients with MIBC and high-risk non-MIBC (NMIBC) who underwent ORC versus RARC in clinical practice. Methods and materials: A nationwide retrospective study in 19 Dutch hospitals including patients with MIBC and high-risk NMIBC treated by ORC (n = 1086) or RARC (n = 386) between January 1, 2012 and December 31, 2015. Primary and secondary outcome measures were median OS and RFS, respectively. Survival outcomes were estimated using Kaplan-Meier curves. A multivariable Cox regression model was developed to adjust for possible confounders and to assess prognostic factors for survival including clinical variables, clinical and pathological disease stage, neoadjuvant therapy and surgical margin status. Results: The median follow-up was 5.1 years (95% confidence interval ([95%CI] 5.0–5.2). The median OS after ORC was 5.0 years (95%CI 4.3–5.6) versus 5.8 years after RARC (95%CI 5.1–6.5). The median RFS was 3.8 years (95%CI 3.1–4.5) after ORC versus 5.0 years after RARC (95%CI 3.9–6.0). After multivariable adjustment, the hazard ratio for OS was 1.00 (95%CI 0.84–1.20) and for RFS 1.08 (95%CI 0.91–1.27) of ORC versus RARC. Patients who underwent ORC were older, had higher preoperative serum creatinine levels and more advanced clinical and pathological disease stage. Conclusion: ORC and RARC resulted in similar intermediate-term OS and RFS in a cohort of almost 1500 MIBC and high-risk NMIBC.

Original language	English
Journal	Urologic Oncology: Seminars and Original Investigations
Early online date	2021
DOIs	https://doi.org/10.1016/j.urolonc.2021.06.018
Publication status	E-pub ahead of print - 2021

Access to Document

10.1016/j.urolonc.2021.06.018

Cite this

Hinsenveld, F. J., Boormans, J. L., van der Poel, H. G., van der Schoot, D. K. E., Vis, A. N., Aben, K. K. H., Arends, T. J., Ausems, P. J., Baselmans, D., Berger, C. P. A. M., Berrens, A., Bickerstaffe, H., Bos, S. D., Braam, M., Buddingh, K. T., Claus, S., Dekker, K., van Doeveren, T., Einerhand, S. M. H., ... van Beek, S. C. (2021). Intermediate-term survival of robot-assisted versus open radical cystectomy for muscle-invasive and high-risk non-muscle invasive bladder cancer in The Netherlands. Urologic Oncology: Seminars and Original Investigations. https://doi.org/10.1016/j.urolonc.2021.06.018

@article{148c70b8381741019705603e566e90b3,

title = "Intermediate-term survival of robot-assisted versus open radical cystectomy for muscle-invasive and high-risk non-muscle invasive bladder cancer in The Netherlands",

abstract = "Background: Radical cystectomy with pelvic lymph node dissection is the recommended treatment in non-metastatic muscle-invasive bladder cancer (MIBC). In randomised trials, robot-assisted radical cystectomy (RARC) showed non-inferior short-term oncological outcomes compared with open radical cystectomy (ORC). Data on intermediate and long-term oncological outcomes of RARC are limited. Objective: To assess the intermediate-term overall survival (OS) and recurrence-free survival (RFS) of patients with MIBC and high-risk non-MIBC (NMIBC) who underwent ORC versus RARC in clinical practice. Methods and materials: A nationwide retrospective study in 19 Dutch hospitals including patients with MIBC and high-risk NMIBC treated by ORC (n = 1086) or RARC (n = 386) between January 1, 2012 and December 31, 2015. Primary and secondary outcome measures were median OS and RFS, respectively. Survival outcomes were estimated using Kaplan-Meier curves. A multivariable Cox regression model was developed to adjust for possible confounders and to assess prognostic factors for survival including clinical variables, clinical and pathological disease stage, neoadjuvant therapy and surgical margin status. Results: The median follow-up was 5.1 years (95% confidence interval ([95%CI] 5.0–5.2). The median OS after ORC was 5.0 years (95%CI 4.3–5.6) versus 5.8 years after RARC (95%CI 5.1–6.5). The median RFS was 3.8 years (95%CI 3.1–4.5) after ORC versus 5.0 years after RARC (95%CI 3.9–6.0). After multivariable adjustment, the hazard ratio for OS was 1.00 (95%CI 0.84–1.20) and for RFS 1.08 (95%CI 0.91–1.27) of ORC versus RARC. Patients who underwent ORC were older, had higher preoperative serum creatinine levels and more advanced clinical and pathological disease stage. Conclusion: ORC and RARC resulted in similar intermediate-term OS and RFS in a cohort of almost 1500 MIBC and high-risk NMIBC.",

keywords = "Bladder cancer, Cystectomy, Muscle invasive, Robot, Survival",

author = "Hinsenveld, {Florentien J.} and Boormans, {Joost L.} and {van der Poel}, {Henk G.} and {van der Schoot}, {Deric K. E.} and Vis, {Andr{\'e} N.} and Aben, {Katja K. H.} and Arends, {T. J.} and Ausems, {P. J.} and D. Baselmans and Berger, {C. P. A. M.} and A. Berrens and H. Bickerstaffe and Bos, {S. D.} and M. Braam and Buddingh, {K. T.} and S. Claus and K. Dekker and {van Doeveren}, T. and Einerhand, {S. M. H.} and Fossion, {L. M. C. L.} and {van Gennep}, {E. J.} and {van Ginkel}, N. and Palacios, {L. A. Grondhuis} and Hermans, {T. J. N.} and Hobijn, {M. M.} and {van Huystee}, {S. H.} and M. Jaspers-Valentijn and Klaver, {O. S.} and Koldewijn, {E. L.} and {On behalf of the Dutch Cystectomy Snapshot Group} and L. Korsten and A. Lenting and Lentjes, {K. J.} and Luiting, {H. B.} and {van der Meer}, S. and Nieuwenhuijzen, {J. A.} and Noordzij, {M. A.} and Nooter, {R. I.} and Notenboom, {C. A. W.} and Oomen, {R. J. A.} and {van Roermund}, {J. G. H.} and {de Rooij}, J. and H. Roshani and Schrier, {B. P.} and {van der Slot}, {M. A.} and Somford, {D. M.} and Stelwagen, {P. J.} and Stroux, {A. M. A.} and {van der West}, A. and Wijsman, {B. P.} and Windt, {W. A. K. M.} and {van Zanten}, P. and {van Beek}, {Sytse C.}",

note = "Funding Information: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors Publisher Copyright: {\textcopyright} 2021 The Authors Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

doi = "10.1016/j.urolonc.2021.06.018",

language = "English",

journal = "Urologic Oncology",

issn = "1078-1439",

publisher = "Elsevier Inc.",

}

Hinsenveld, FJ, Boormans, JL, van der Poel, HG, van der Schoot, DKE, Vis, AN, Aben, KKH, Arends, TJ, Ausems, PJ, Baselmans, D, Berger, CPAM, Berrens, A, Bickerstaffe, H, Bos, SD, Braam, M, Buddingh, KT, Claus, S, Dekker, K, van Doeveren, T, Einerhand, SMH, Fossion, LMCL, van Gennep, EJ, van Ginkel, N, Palacios, LAG, Hermans, TJN, Hobijn, MM, van Huystee, SH, Jaspers-Valentijn, M, Klaver, OS, Koldewijn, EL, On behalf of the Dutch Cystectomy Snapshot Group, Korsten, L, Lenting, A, Lentjes, KJ, Luiting, HB, van der Meer, S, Nieuwenhuijzen, JA, Noordzij, MA, Nooter, RI, Notenboom, CAW, Oomen, RJA, van Roermund, JGH, de Rooij, J, Roshani, H, Schrier, BP, van der Slot, MA, Somford, DM, Stelwagen, PJ, Stroux, AMA, van der West, A, Wijsman, BP, Windt, WAKM, van Zanten, P & van Beek, SC 2021, 'Intermediate-term survival of robot-assisted versus open radical cystectomy for muscle-invasive and high-risk non-muscle invasive bladder cancer in The Netherlands', Urologic Oncology: Seminars and Original Investigations. https://doi.org/10.1016/j.urolonc.2021.06.018

Intermediate-term survival of robot-assisted versus open radical cystectomy for muscle-invasive and high-risk non-muscle invasive bladder cancer in The Netherlands. / Hinsenveld, Florentien J.; Boormans, Joost L.; van der Poel, Henk G. et al.

In: Urologic Oncology: Seminars and Original Investigations, 2021.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Intermediate-term survival of robot-assisted versus open radical cystectomy for muscle-invasive and high-risk non-muscle invasive bladder cancer in The Netherlands

AU - Hinsenveld, Florentien J.

AU - Boormans, Joost L.

AU - van der Poel, Henk G.

AU - van der Schoot, Deric K. E.

AU - Vis, André N.

AU - Aben, Katja K. H.

AU - Arends, T. J.

AU - Ausems, P. J.

AU - Baselmans, D.

AU - Berger, C. P. A. M.

AU - Berrens, A.

AU - Bickerstaffe, H.

AU - Bos, S. D.

AU - Braam, M.

AU - Buddingh, K. T.

AU - Claus, S.

AU - Dekker, K.

AU - van Doeveren, T.

AU - Einerhand, S. M. H.

AU - Fossion, L. M. C. L.

AU - van Gennep, E. J.

AU - van Ginkel, N.

AU - Palacios, L. A. Grondhuis

AU - Hermans, T. J. N.

AU - Hobijn, M. M.

AU - van Huystee, S. H.

AU - Jaspers-Valentijn, M.

AU - Klaver, O. S.

AU - Koldewijn, E. L.

AU - On behalf of the Dutch Cystectomy Snapshot Group

AU - Korsten, L.

AU - Lenting, A.

AU - Lentjes, K. J.

AU - Luiting, H. B.

AU - van der Meer, S.

AU - Nieuwenhuijzen, J. A.

AU - Noordzij, M. A.

AU - Nooter, R. I.

AU - Notenboom, C. A. W.

AU - Oomen, R. J. A.

AU - van Roermund, J. G. H.

AU - de Rooij, J.

AU - Roshani, H.

AU - Schrier, B. P.

AU - van der Slot, M. A.

AU - Somford, D. M.

AU - Stelwagen, P. J.

AU - Stroux, A. M. A.

AU - van der West, A.

AU - Wijsman, B. P.

AU - Windt, W. A. K. M.

AU - van Zanten, P.

AU - van Beek, Sytse C.

N1 - Funding Information: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors Publisher Copyright: © 2021 The Authors Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021

Y1 - 2021

N2 - Background: Radical cystectomy with pelvic lymph node dissection is the recommended treatment in non-metastatic muscle-invasive bladder cancer (MIBC). In randomised trials, robot-assisted radical cystectomy (RARC) showed non-inferior short-term oncological outcomes compared with open radical cystectomy (ORC). Data on intermediate and long-term oncological outcomes of RARC are limited. Objective: To assess the intermediate-term overall survival (OS) and recurrence-free survival (RFS) of patients with MIBC and high-risk non-MIBC (NMIBC) who underwent ORC versus RARC in clinical practice. Methods and materials: A nationwide retrospective study in 19 Dutch hospitals including patients with MIBC and high-risk NMIBC treated by ORC (n = 1086) or RARC (n = 386) between January 1, 2012 and December 31, 2015. Primary and secondary outcome measures were median OS and RFS, respectively. Survival outcomes were estimated using Kaplan-Meier curves. A multivariable Cox regression model was developed to adjust for possible confounders and to assess prognostic factors for survival including clinical variables, clinical and pathological disease stage, neoadjuvant therapy and surgical margin status. Results: The median follow-up was 5.1 years (95% confidence interval ([95%CI] 5.0–5.2). The median OS after ORC was 5.0 years (95%CI 4.3–5.6) versus 5.8 years after RARC (95%CI 5.1–6.5). The median RFS was 3.8 years (95%CI 3.1–4.5) after ORC versus 5.0 years after RARC (95%CI 3.9–6.0). After multivariable adjustment, the hazard ratio for OS was 1.00 (95%CI 0.84–1.20) and for RFS 1.08 (95%CI 0.91–1.27) of ORC versus RARC. Patients who underwent ORC were older, had higher preoperative serum creatinine levels and more advanced clinical and pathological disease stage. Conclusion: ORC and RARC resulted in similar intermediate-term OS and RFS in a cohort of almost 1500 MIBC and high-risk NMIBC.

AB - Background: Radical cystectomy with pelvic lymph node dissection is the recommended treatment in non-metastatic muscle-invasive bladder cancer (MIBC). In randomised trials, robot-assisted radical cystectomy (RARC) showed non-inferior short-term oncological outcomes compared with open radical cystectomy (ORC). Data on intermediate and long-term oncological outcomes of RARC are limited. Objective: To assess the intermediate-term overall survival (OS) and recurrence-free survival (RFS) of patients with MIBC and high-risk non-MIBC (NMIBC) who underwent ORC versus RARC in clinical practice. Methods and materials: A nationwide retrospective study in 19 Dutch hospitals including patients with MIBC and high-risk NMIBC treated by ORC (n = 1086) or RARC (n = 386) between January 1, 2012 and December 31, 2015. Primary and secondary outcome measures were median OS and RFS, respectively. Survival outcomes were estimated using Kaplan-Meier curves. A multivariable Cox regression model was developed to adjust for possible confounders and to assess prognostic factors for survival including clinical variables, clinical and pathological disease stage, neoadjuvant therapy and surgical margin status. Results: The median follow-up was 5.1 years (95% confidence interval ([95%CI] 5.0–5.2). The median OS after ORC was 5.0 years (95%CI 4.3–5.6) versus 5.8 years after RARC (95%CI 5.1–6.5). The median RFS was 3.8 years (95%CI 3.1–4.5) after ORC versus 5.0 years after RARC (95%CI 3.9–6.0). After multivariable adjustment, the hazard ratio for OS was 1.00 (95%CI 0.84–1.20) and for RFS 1.08 (95%CI 0.91–1.27) of ORC versus RARC. Patients who underwent ORC were older, had higher preoperative serum creatinine levels and more advanced clinical and pathological disease stage. Conclusion: ORC and RARC resulted in similar intermediate-term OS and RFS in a cohort of almost 1500 MIBC and high-risk NMIBC.

KW - Bladder cancer

KW - Cystectomy

KW - Muscle invasive

KW - Robot

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85111048467&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2021.06.018

DO - 10.1016/j.urolonc.2021.06.018

M3 - Article

C2 - 34303597

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

ER -

Intermediate-term survival of robot-assisted versus open radical cystectomy for muscle-invasive and high-risk non-muscle invasive bladder cancer in The Netherlands

Abstract

Access to Document

Other files and links

Cite this